July 22, 2026

Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma

Preclinical research showed antiproliferative activity against NRAS-mutant melanoma cell lines and antitumor activity against preclinical melanoma models.

The ASCO Post

July 09, 2026

Targeting BCL2 May Overcome Acquired Resistance in BRAF-Mutant Melanoma

Targeting BCL2 family proteins may counteract acquired resistance to BRAF and MEK inhibition in patients with BRAF-mutant metastatic melanoma, according to findings from a preclinical study published ...

The ASCO Post

July 06, 2026

Preclinical Research Shows IFN-γ May Attenuate Neutrophil Response to Cancer Immunotherapy

Researchers have discovered that the type II interferon, interferon-γ, may impact how neutrophils react to immunotherapy, either supporting or blocking the treatment for patients with cancer, accordin...

The ASCO Post

June 24, 2026

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

UCI Health

June 03, 2026

Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma

The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared wit...

The ASCO Post

May 08, 2026

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

A cohort study showed that patients with melanoma who received BRAF or MEK inhibitor therapy commonly experienced hypertension and mild cardiac dysfunction, supporting baseline cardiotoxicity risk str...

The ASCO Post

May 04, 2026

CLL Linked to Increased Skin Cancer Risk and Mortality

In a nationwide population–based cohort study reported in JAMA Dermatology, Blomberg Drejøe et al evaluated the long-term risk of skin cancer and related outcomes among patients with chronic lymphocyt...

The ASCO Post

May 04, 2026

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation

In a systematic review and meta-analysis published in JAMA Dermatology, Laiouar-Pedari et al evaluated the real-world diagnostic performance of artificial intelligence (AI)–assisted dermoscopy for mel...

The ASCO Post

May 01, 2026

Melanoma: Gut Microbiome May Help Predict Recurrence After Immunotherapy

Gut bacterial markers may be able to predict recurrence in patients with high-risk melanoma receiving adjuvant immune checkpoint inhibition, according to study findings published in Cell. 

The ASCO Post

April 17, 2026

Melanoma: Can AI Enable Diagnosis Prediction?

Assessment of machine-learning models tested on Swedish registry data enabled more accurate melanoma diagnosis prediction, with added health-care code, age, sex, and medication information for improve...

The ASCO Post